Pfizer applies to U.S. Food and Drug Administration for emergency use of coronavirus vaccine

US pharmaceutical company Pfizer has asked for the new type of coronavirus vaccine to be allowed for emergency use in the US. Pfizer / BioNTech's vaccine was announced to provide more than 95 percent protection in the results of third-stage clinical trials.

Pfizer and Turkish scientist Prof. Dr. BioNTech, a German biotech company co-founded by Uğur şahin, explained that the protection of the vaccine as well as a good safety record means that it is suitable for emergency use.

HE ALSO STARTED WORKING IN EUROPE

Pfizer and BioNTech, which have applied to the US Food and Drug Administration (FDA) for emergency use, have already started applying to institutions in Europe.

HE DECLARED IT 95 PERCENT EFFECTIVE

American pharmaceutical company Pfizer, He announced that the vaccine he developed with BioNTech against the new type of coronavirus had concluded Phase 3 trials and that the vaccine was 95 percent effective against the virus.

IT IS PLANNED TO PRODUCE 

1.3 BILLION DOSES OF THE VACCINE BY THE END OF 2021.It was noted that the vaccine was consistent with age, ethnic group and gender and met the FDA's necessary safety criteria. Pfizer plans to produce 50 million doses of the vaccine in 2020 and 1.3 billion by the end of 2021.